News and Announcements

Members of the WIND-PSC project, including the steering committee, staff, and investigators from several of the sites currently enrolling...

Quotes from interviews of patients living with PSC describing their fatigue, presented as a poster at AASLD's The Liver Meeting 2024 ....

Today, March 27, 2025, Chemomab Therapeutics issued a press release announcing results from the Open Label Extension (OLE) section of the SPRING trial, which offered SPRING participants the opportunity to receive nebokitug (CM-101) for an additional 33 weeks (up to 48 weeks of exposure to nebokitug). PSC Partners is encouraged by the positive nebokitug OLE data shared in the press release. Key takeaways from the press release that are important to patients: More than 90% of

A new survey outside the Registry that focuses on understanding and improving the care of people living with PSC is now available. Every...

On February 19, 2025, Chemomab Therapeutics issued a press release announcing plans for a Phase 3 clinical trial for the treatment of PSC. The full press release is available on the Chemomab website. The investigational drug being tested has been named nebokitug, previously studied in PSC in the SPRING Study as CM-101. PSC Partners is encouraged by the news that a potential drug for PSC is moving forward into the final stages of the drug approval process (Phase 3 clinical